Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Harvard Business School
Farmers Insurance
Argus Health
Citi
AstraZeneca
Dow
Federal Trade Commission
Teva

Generated: October 23, 2018

DrugPatentWatch Database Preview

Wyeth Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for WYETH PHARMS, and what generic alternatives to WYETH PHARMS drugs are available?

WYETH PHARMS has thirty-seven approved drugs.

There are eighteen US patents protecting WYETH PHARMS drugs.

Summary for Wyeth Pharms
US Patents:18
Tradenames:35
Ingredients:21
NDAs:37

Drugs and US Patents for Wyeth Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms PROTONIX IV pantoprazole sodium INJECTABLE;IV (INFUSION) 020988-001 Mar 22, 2001 AP RX Yes Yes 7,351,723*PED ➤ Sign Up Y ➤ Sign Up
Wyeth Pharms ZOSYN piperacillin sodium; tazobactam sodium INJECTABLE;INJECTION 050684-004 Oct 22, 1993 AP RX Yes Yes 7,915,229 ➤ Sign Up Y ➤ Sign Up
Wyeth Pharms Inc PIPRACIL piperacillin sodium INJECTABLE;INJECTION 050545-003 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up
Wyeth Pharms ZOSYN IN PLASTIC CONTAINER piperacillin sodium; tazobactam sodium INJECTABLE;INJECTION 050750-003 Feb 24, 1998 RX Yes Yes 7,915,229 ➤ Sign Up Y ➤ Sign Up
Wyeth Pharms PROTONIX pantoprazole sodium FOR SUSPENSION, DELAYED RELEASE;ORAL 022020-001 Nov 14, 2007 RX Yes Yes 7,550,153*PED ➤ Sign Up Y ➤ Sign Up
Wyeth Pharms Inc INDERIDE-80/25 hydrochlorothiazide; propranolol hydrochloride TABLET;ORAL 018031-002 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Wyeth Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms EFFEXOR XR venlafaxine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020699-003 Oct 20, 1997 6,444,708*PED ➤ Sign Up
Wyeth Pharms Inc EFFEXOR venlafaxine hydrochloride TABLET;ORAL 020151-003 Dec 28, 1993 5,916,923 ➤ Sign Up
Wyeth Pharms Inc PREMPRO (PREMARIN;CYCRIN) estrogens, conjugated; medroxyprogesterone acetate TABLET;ORAL-28 020303-001 Dec 30, 1994 5,210,081 ➤ Sign Up
Wyeth Pharms Inc LODINE etodolac CAPSULE;ORAL 018922-003 Jan 31, 1991 4,076,831 ➤ Sign Up
Wyeth Pharms Inc EFFEXOR venlafaxine hydrochloride TABLET;ORAL 020151-004 Dec 28, 1993 5,916,923 ➤ Sign Up
Wyeth Pharms PREMPRO estrogens, conjugated; medroxyprogesterone acetate TABLET;ORAL-28 020527-005 Jun 4, 2003 5,210,081 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for WYETH PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 0.09 mg/0.02 mg ➤ Subscribe 2007-10-05
➤ Subscribe Delayed-release Tablets 20 mg and 40 mg ➤ Subscribe 2004-02-02
➤ Subscribe Extended-release Tablets 50 mg and 100 mg ➤ Subscribe 2012-02-29
➤ Subscribe Tablets 25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg ➤ Subscribe 2005-11-03
➤ Subscribe Extended-release Tablets 37.5 mg, 75 mg and 150 mg ➤ Subscribe 2007-05-03
➤ Subscribe For Injection 12 g/1.5 g per vial (pharmacy bulk) ➤ Subscribe 2011-12-06
➤ Subscribe Extended-release Tablets 25 mg ➤ Subscribe 2015-05-08

Supplementary Protection Certificates for Wyeth Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB99/008 United Kingdom ➤ Sign Up PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
C0030 France ➤ Sign Up PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
00095 Netherlands ➤ Sign Up PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
C0032 Belgium ➤ Sign Up PRODUCT NAME: PANTOPRAZOL. NATR. SESQUIHYDRAS PANTOPRAZOLE; NAT. REGISTRATION NO/DATE: 127 IS 98 F 3 19960222; FIRST REGISTRATION: SE 12131 19940506
0814 Netherlands ➤ Sign Up PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
09/028 Ireland ➤ Sign Up PRODUCT NAME: BAZEDOXIFENE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/09/511/001-004 20090417
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
US Army
Covington
Boehringer Ingelheim
Queensland Health
Express Scripts
McKesson
AstraZeneca
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.